PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Phase I, Single Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease
- Conditions
- Alzheimer's Disease
- Interventions
- Drug: PlaceboBiological: PF-04360365
- First Posted Date
- 2008-02-05
- Last Posted Date
- 2010-12-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 20
- Registration Number
- NCT00607308
- Locations
- 🇯🇵
Pfizer Investigational Site, Kyoto, Japan
A Multi-Center Trial To Evaluate The Safety And Efficacy Of Pegaptanib Sodium(Macugen) Injected Into The Eye Every 6 Weeks For Up To 2 Years For Macular Swelling Associated With Diabetes, With An Open-Label Macugen Year Extension.
- Conditions
- Macular Edema Associated With Diabetes Mellitus
- Interventions
- Drug: Standard of Care
- First Posted Date
- 2008-01-31
- Last Posted Date
- 2018-11-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 317
- Registration Number
- NCT00605280
- Locations
- 🇬🇧
Pfizer Investigational Site, Sheffield, United Kingdom
Comparison Of 4 CP-690,550 Doses Vs. Placebo, Each Combined With Methotrexate, For The Treatment Of Rheumatoid Arthritis in Japan
- First Posted Date
- 2008-01-29
- Last Posted Date
- 2013-01-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 140
- Registration Number
- NCT00603512
- Locations
- 🇯🇵
Pfizer Investigational Site, Niigata, Japan
Study of CP-751,871 in Combination With Carboplatin and Paclitaxel in Advanced Lung Cancer
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2008-01-29
- Last Posted Date
- 2013-04-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 19
- Registration Number
- NCT00603538
- Locations
- 🇯🇵
Pfizer Investigational Site, Chuo-ku, Tokyo, Japan
An Effectiveness and Safety Study of PF-04383119 for the Treatment of Pain in Interstitial Cystitis
- First Posted Date
- 2008-01-28
- Last Posted Date
- 2021-05-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 65
- Registration Number
- NCT00601484
- Locations
- 🇺🇸
Hartford Hospital, Hartford, Connecticut, United States
🇺🇸Connecticut Urological Research at Grove Hill, New Britain, Connecticut, United States
🇺🇸SD Uro-Research, San Diego, California, United States
Drug Use Investigation of Somatropin for GHD-ADULTS.
- First Posted Date
- 2008-01-28
- Last Posted Date
- 2014-02-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 230
- Registration Number
- NCT00601419
A Study Of AG-013736 (Axitinib) Or Bevacizumab (Avastin) In Combination With Paclitaxel And Carboplatin In Patients With Advanced Lung Cancer.
- Conditions
- Non-Small-Cell Lung CarcinomaAdenocarcinoma
- Interventions
- First Posted Date
- 2008-01-25
- Last Posted Date
- 2013-11-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 118
- Registration Number
- NCT00600821
- Locations
- 🇬🇧
Pfizer Investigational Site, Surrey, United Kingdom
A Study To Compare Pregabalin/PF-00489791 Combination Versus Pregabalin Alone In Post-Herpetic Neuralgia
- Conditions
- Postherpetic Neuralgia
- Interventions
- First Posted Date
- 2008-01-24
- Last Posted Date
- 2021-08-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 72
- Registration Number
- NCT00599638
- Locations
- 🇺🇸
Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, Florida, United States
🇺🇸Arthritis Associates of South Florida, Delray Beach, Florida, United States
🇺🇸Delray Research Associates, Delray Beach, Florida, United States
Study Of Sunitinib Plus FOLFOX In Patients With Solid Tumors
- First Posted Date
- 2008-01-24
- Last Posted Date
- 2015-07-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 53
- Registration Number
- NCT00599924
- Locations
- 🇺🇸
Pfizer Investigational Site, Dallas, Texas, United States
A Study to Evaluate the Blood Levels, Safety, and Tolerability of PF-00734200 in Subjects With Impaired Kidney Function and Normal Kidney Function
- First Posted Date
- 2008-01-17
- Last Posted Date
- 2017-03-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 30
- Registration Number
- NCT00596518
- Locations
- 🇺🇸
Pfizer Investigational Site, Knoxville, Tennessee, United States